Novel discoveries on aggressive NK-cell leukemia pave the way for new treatments

April 19, 2018, University of Helsinki

An international research consortium led by researchers from the University of Helsinki, Finland, has discovered new information related to a rare form of leukemia called aggressive NK-cell leukemia. Potential new treatment options were found which are highly warranted as currently this disease usually leads to rapid death of patients. The study was published in Nature Communications.

Aggressive NK-cell (ANKL) is a cancer in which consist of , a part of our immune system in normal conditions. The disease is very rare and aggressive: with the current (cytostatic drugs and hematopoietic stem cell transplantation) patients usually survive only a couple of months. This leukemia type is more common in the Asian population. However, related diseases such as NK/T-cell lymphomas occur also in western countries.

Together with Japanese, South-Korean, Taiwanese and US research teams, the researchers from the University of Helsinki aimed to discover which genetic defects are typical in this type of leukemia.

"ANKL patients often had mutations in the STAT3 and DDX3X genes which points towards partly shared genetic background with other NK- and T-cell malignancies," says Professor Satu Mustjoki, University of Helsinki, whose group initially discovered somatic STAT3 mutations in LGL leukemia.

By comparing the exome sequencing data from ANKL patients to previously published datasets from NK/T-cell lymphoma patients, researchers also uncovered novel gene amplifications in the JAK-STAT signaling pathway. In some cases, the amplified regions in the genome also included the PD-L1 gene which has therapeutic potential. In other lymphoma types, tumors with amplifications in the PD-L1 gene have responded well to novel immune checkpoint inhibitor therapies.

Researchers also aimed to discover novel potential drugs for the treatment of ANKL by testing the ability of over 400 different drugs to kill malignant and normal NK cells in cell culture conditions. Some potential drug candidates were discovered: NK were especially sensitive for drugs which inhibit JAK tyrosine kinases and anti-apoptotic BCL family members. JAK inhibitors inhibit the same signaling pathway in which genetic alterations were discovered in ANKL .

"JAK inhibitors, currently used in the treatment of rheumatoid arthritis and some other hematological diseases, could potentially improve the treatment of various NK-cell malignancies," says MD/Ph.D. student Olli Dufva who is the first author in the publication.

Explore further: Finnish researchers identify the cause for LGL leukemia

More information: Olli Dufva et al. Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target, Nature Communications (2018). DOI: 10.1038/s41467-018-03987-2

Related Stories

Finnish researchers identify the cause for LGL leukemia

May 16, 2012
Researchers of the University of Helsinki, Helsinki University Central Hospital and Institute for Molecular Medicine Finland, have discovered that a mutation in the STAT3 gene is an underlying cause for LGL leukemia. Since ...

Study links mutations in notch gene to role in B cell cancers

October 23, 2017
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell ...

An epigenetic lesion could be responsible for acute T-cell leukemia

March 30, 2017
Researchers from the Epigenetics and Cancer Biology Program (PEBC) led by Dr. Manel Esteller at the Bellvitge Biomedical Research Institute (IDIBELL) have discovered how an epigenetic lesion can lead to T-cell acute lymphoblastic ...

The HLF-gene controls the generation of our long-term immune system

November 22, 2017
A research group at Lund University in Sweden has found that when the HLF (hepatic leukemia factor) gene –which is expressed in immature blood cells – does not shut down on time, we are unable to develop a functional ...

New drug cocktail unlocks potential of new leukemia treatment

January 23, 2017
A new combination of drugs, tested by University of Manchester scientists, has significantly enhanced the survival of laboratory mice with lymphoma.

New gene mutations found in white blood cells in patients with rheumatoid arthritis

June 21, 2017
Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers have found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.